GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

@inproceedings{Sposito2018GLP1RAsIT,
  title={GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data},
  author={Andrei C Sposito and Otavio Berwanger and Luiz S{\'e}rgio F de Carvalho and Jos{\'e} Francisco Kerr Saraiva},
  booktitle={Cardiovascular diabetology},
  year={2018}
}
Patients with type 2 diabetes (T2DM) have a substantial risk of developing cardiovascular disease. The strong connection between the severity of hyperglycaemia, metabolic changes secondary to T2DM and vascular damage increases the risk of macrovascular complications. There is a challenging demand for the development of drugs that control hyperglycaemia and influence other metabolic risk factors to improve cardiovascular outcomes such as cardiovascular death, nonfatal myocardial infarction… CONTINUE READING
BETA
33
Twitter Mentions

Similar Papers

References

Publications referenced by this paper.
SHOWING 1-10 OF 162 REFERENCES

Review of head‐to‐head comparisons of glucagon‐like peptide‐1 receptor agonists

  • Diabetes, obesity & metabolism
  • 2016
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis

  • Trends in Endocrinology & Metabolism
  • 2010
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

8th edition

IDF Diabetes Atla
  • 2017. https ://www.idf.org/e-libra ry/ welco me.html. Accessed 16 Feb
  • 2018
VIEW 1 EXCERPT